Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
about
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryFludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomasBendamustine as a model for the activity of alkylating agents.Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.Bendamustine in the treatment of non-Hodgkin's lymphomas.Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.Bendamustine: new perspective for an old drug in lymphoproliferative disorders.Bendamustine: role and evidence in lymphoma therapy, an overview.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
P2860
Q28088365-B69432E2-6A54-465C-9E02-2D19DEE9C1A6Q33361458-4B2D7326-3D4A-44EB-8133-1FEAB8475273Q33375169-8DB19212-5308-4085-B502-C088D1F8374CQ33395564-9A254AF3-264A-4AAA-8314-8480C6530F66Q33400871-14D35695-C29E-4A0D-A61B-5A0646FCFD2DQ33409872-8AADB174-519C-4E32-A7F8-60A773AE2130Q33437806-FE3C1040-5583-4282-B8D2-DA3C20F29334Q33440251-F0A5F467-7851-42A4-A137-444FCD8BCEACQ35096335-87969D28-0F32-4AB7-AEB1-82B3BDC96C2EQ37179377-970C963F-036A-46C0-B571-9C7C56DBA7B9Q37480786-4ECCE183-61C6-4101-80A0-A0DA261955F8Q37771253-E1208784-0318-4E23-B295-286D9A4FFD49Q37788236-566EBAD3-3A12-493E-B920-0D08FB2B5421Q37810270-BCD39794-B5FA-4015-A655-D9AFB9A4C7D1Q38158084-1A58AC77-B9E6-4223-BFA8-32BBEBD22B96Q38642648-61461281-8682-44FE-9984-4362A54721C7Q38700745-A88DE9E5-4B82-4601-990B-F727D3FF6917Q38862949-72A2F786-95AB-4F5D-A3A5-49E293494315Q38947107-798B2005-C809-423D-811F-5A5F272A93F0Q39031363-EF7AE0B1-F46B-4B03-AD4D-313F9CB5305BQ40831512-B43EADBD-36CD-4ABB-9130-32B6DFA770F8Q44781560-B8C6A451-69ED-4FF5-88ED-9826FEFE5DB7Q52895479-9BD30D74-9F93-413D-B5E1-2B04F966E594Q54214982-7CDF9751-2B4F-45AE-8C5E-6880F6890AB9Q55359395-3A99EB07-6498-4E0B-BBA6-A481596DD55D
P2860
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
type
label
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
prefLabel
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
P2093
P356
P1433
P1476
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
P2093
E Weidmann
H Schuppert
P S Mitrou
P304
P356
10.1093/ANNONC/MDF189
P577
2002-08-01T00:00:00Z